NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...

Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their share prices, thanks to the booming ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors ...

Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of inv ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Sangamo Therapeutics (NASDAQ:SGMO) faced a significant setback as Pfizer announced the termination of their partnership to co ...